The FDA approved the first cholesterol pill that lowers LDL as much as the injections do.
On July 16 the agency cleared Merck's LIPFENDRA (enlicitide), a once-daily 20 milligram tablet, as the first oral drug in a class called PCSK9 inhibitors. Merck's announcement ↗ put the case plainly. In two Phase 3 trials the pill cut LDL cholesterol, the kind that builds up in artery walls, by 56 percent and 59 percent against placebo. Those are the numbers injectable PCSK9 drugs post, and until now the only way to get them was a shot every two to four weeks.
What a PCSK9 inhibitor does
PCSK9 is a protein that tells the liver to tear down its own LDL receptors. Fewer receptors means less LDL pulled out of the blood. Block PCSK9 and the receptors survive, the liver keeps clearing cholesterol, and LDL falls. The two approved injectables, Amgen's Repatha (evolocumab) and Regeneron and Sanofi's Praluent (alirocumab), are antibodies. They work, but they are large proteins that the gut would digest, so they have to be injected.
Enlicitide reaches the same target with a much smaller molecule: a macrocyclic peptide, a short chain of amino acids locked into a ring. The ring is the trick. A loose peptide is chewed up by stomach acid and gut enzymes within minutes. A tightly cyclized one can survive the trip intact and reach the bloodstream. That is what lets a PCSK9 blocker be swallowed instead of injected.
The price, and the catch
Merck listed LIPFENDRA at 315 dollars a month, roughly a third of the 700 to 900 dollars a month the injectable antibodies carry. A daily pill at a third the price is why this approval reaches past cardiologists to ordinary patients who never wanted a needle in the first place.
The catch is what the approval rests on. The FDA cleared enlicitide on LDL, a lab number, not on proof that it prevents heart attacks. The trial built to answer that question, CORALreef Outcomes, has enrolled more than 14,500 people and is not due to report until late 2029, a point independent cardiology coverage ↗ flagged on approval day. Lowering LDL this much has meant fewer cardiovascular events for every prior drug that does it, so the expectation is strong. It is not yet proven for this molecule.
Why a peptide chemist cares
Enlicitide is evidence that macrocyclic peptides can be made oral and made at scale. We covered the manufacturing side in May ↗, when Merck published an engineered-enzyme route that cut the synthesis by more than half. The same ring chemistry sits under other oral-peptide bets, including Chugai's KRAS macrocycle LUNA18 ↗. An approved, priced, once-daily macrocyclic peptide is the clearest sign yet that the class has cleared its chemistry problem. The question that remains is commercial, not molecular: whether a pill that matches the shots at a third the price can pull a market that statins already crowd.